^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Viral entry inhibitor

    Related drugs:
    5d
    A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Initiation date: Feb 2026 --> Jun 2026
    Trial initiation date
    |
    CD4 (CD4 Molecule)
    9d
    A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide (clinicaltrials.gov)
    P3, N=150, Recruiting, Vir Biotechnology, Inc.
    Trial initiation date
    9d
    A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study) (clinicaltrials.gov)
    P3, N=150, Not yet recruiting, Huahui Health
    New P3 trial
    12d
    Non-Invasive Programmed Stimulation (NIPS) to Guide the Subsequent VT Therapeutic Strategies (clinicaltrials.gov)
    P=N/A, N=51, Recruiting, IRCCS Ospedale San Raffaele | Not yet recruiting --> Recruiting
    Enrollment open
    14d
    Papillary Thyroid Carcinoma in a Patient With a Germline Titin (TTN) Mutation. (PubMed, Cureus)
    Owing to the large size of the TTN gene, recurrent mutations are frequently observed across cancer datasets, but the clinical and biological significance of these alterations, particularly in the germline setting, remains incompletely understood. This case presents a patient with a germline TTN mutation who was diagnosed with papillary thyroid carcinoma after he developed amiodarone-induced thyrotoxicosis.
    Journal
    |
    TTN (Titin)
    15d
    ENTRANCE: A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV (clinicaltrials.gov)
    P1, N=107, Active, not recruiting, ViiV Healthcare | Trial completion date: Mar 2028 --> Sep 2028
    Trial completion date • Trial initiation date
    |
    CD4 (CD4 Molecule)
    16d
    AMIODETECT: Comparative Efficacy of 100-, 200-, & 400-mg Amiodarone in Patients With Paroxysmal AF Depending on Plasma Concentration (clinicaltrials.gov)
    P4, N=80, Enrolling by invitation, Tomsk National Research Medical Center of the Russian Academy of Sciences
    New P4 trial
    17d
    ENTRANCE: A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV (clinicaltrials.gov)
    P1, N=100, Active, not recruiting, ViiV Healthcare | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD4 (CD4 Molecule)
    23d
    PATRONUS: Pragmatic Amiodarone Trial to Reduce Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery (clinicaltrials.gov)
    P4, N=0, Withdrawn, Massachusetts General Hospital | N=242 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    30d
    Therapeutic Potential of Cannabinoids in Attenuating Amiodarone-Induced Pulmonary Fibrosis: An in vivo Experimental Study in Wistar Rats. (PubMed, Drug Des Devel Ther)
    In conclusion, the results showed that cannabinoid (O-2545) may offer significant therapeutic potential in mitigating pulmonary toxicity induced by AMIO in rats. This study investigates the possible protective therapeutic effects of (O-2545) on AMIO-induced pulmonary fibrosis in Wistar rats.
    Preclinical • Journal
    |
    TP53 (Tumor protein P53) • TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3) • IL1B (Interleukin 1, beta)
    2ms
    ARN-75039 Lassa Fever Treatment in West Africa (clinicaltrials.gov)
    P2, N=135, Recruiting, Arisan Therapeutics, Inc.
    New P2 trial
    2ms
    A multicentre randomised study on percutaneous stellate ganglion block as first-line treatment in patients with electrical storm: the STAR 2 study (2024-520387-34-00)
    P4, N=180, Fondazione IRCCS Policlinico San Matteo
    New P4 trial